United Therapeutics Corporation
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It's Moving
UTHR Earnings Beat Fuels Optimism Despite Revenue Miss as Executives Sell Shares Amid Strong Growth Outlook
- Q4 revenue hit $790.2 million, up 7.3% year-over-year from Tyvaso sales growth, though missing expectations—highlighting robust demand in PAH treatments.
- Earnings per share crushed forecasts at $7.70 versus $6.76 expected, boosting confidence in operational strength and sparking a sharp post-earnings rally.
- Management forecasts double-digit revenue growth for 2026 and a $4B run rate by late 2027, while recent CEO and COO share sales under pre-set plans add cautionary notes.
UTHR Earnings Beat Fuels Optimism Despite Revenue Miss as Executives Sell Shares Amid Strong Growth Outlook
- Q4 revenue hit $790.2 million, up 7.3% year-over-year from Tyvaso sales growth, though missing expectations—highlighting robust demand in PAH treatments.
- Earnings per share crushed forecasts at $7.70 versus $6.76 expected, boosting confidence in operational strength and sparking a sharp post-earnings rally.
- Management forecasts double-digit revenue growth for 2026 and a $4B run rate by late 2027, while recent CEO and COO share sales under pre-set plans add cautionary notes.
When is the next earnings date for United Therapeutics Corporation (UTHR)?
United Therapeutics Corporation (UTHR) reported its Q4 and full-year 2025 earnings on February 25, 2026, prior to market open. The next earnings release, covering the first quarter of 2026, is expected around late April to early May 2026, consistent with historical patterns such as April 29 to May 5. Investors should monitor company announcements for the precise date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying United Therapeutics stock, anticipating a slight decline in its value.
Financial Health
United Therapeutics is performing well with strong profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring UTHR
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
